Skip to main content

Table 1 Patient and tumor characteristics at baseline

From: Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

  No. of patients Percent
Total 177 100
Menopausal status at diagnosis
 Premenopausal 77 43.5
 Postmenopausal 100 56.5
Pathological tumor size
 T 1 99 55.9
 T 2 58 32.8
 T 3 10 5.6
 T 4 10 5.6
Pathological nodal status
 N 0 95 53.7
 N 1 46 26.0
 N 2 23 13.0
 N 3 9 5.1
 Not evaluated 4 2.3
Pathological stage
 I 63 35.6
 II A 55 31.1
 II B 22 12.4
 III A 14 7.9
 III B 10 5.6
 III C 9 5.1
 Not evaluated 4 2.3
Type of surgery
 Breast-conserving surgery 147 83.1
 Mastectomy 30 16.9
Axillary management
 Sentinel lymph node biopsy alone 95 53.7
 Axillary lymph node dissection 79 44.6
 No surgery 3 1.7
Histological grade
 1 41 23.2
 2 67 37.9
 3 69 39.0
Adjuvant Chemotherapy
 Yes 70 39.5
 No 107 60.5
Adjuvant Endocrine therapy
 Yes 146 82.5
 No 31 17.5